论文部分内容阅读
近年来,中国的肺癌临床研究在肺癌纵隔淋巴结清扫、肺癌的减量性手术、肺癌合并血管和心脏切除的扩大手术上做了许多富有成效的研究,可切除肺癌的术后长期生存率已接近国际先进水平。在肺癌术前、后的辅助治疗和新辅助治疗上也进行了一些前瞻性随机对照临床试验:完全切除术后的早期非小细胞肺癌不需要辅助放疗,而辅助化疗和新辅助化疗的价值仍需继续研究。根据中国的肺癌临床研究现状,急需以循证医学为主导,开展大规模的多中心临床随机对照研究。
In recent years, many clinical studies of lung cancer in China have done a lot of fruitful researches in mediastinal lymphadenectomy of lung cancer, reduction surgery of lung cancer, expansion surgery of lung cancer combined with blood vessel and cardiac resection. The long-term survival rate of resectable lung cancer is close to International advanced level. There are also prospective randomized controlled trials of adjuvant therapy and neoadjuvant therapy for lung cancer before and after surgery: adjuvant radiotherapy and neoadjuvant chemotherapy are not required for adjuvant chemotherapy and neoadjuvant chemotherapy in patients with early stage non-small cell lung cancer after total resection Need to continue research. According to the clinical research status of lung cancer in China, it is urgent to take evidence-based medicine as the leading factor to carry out a large-scale randomized multicenter clinical study.